Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers.
A fluorescent imaging agent developed by Vergent Bioscience Inc. enables visualization of elusive and previously undetected tumors, a phase II study presented last week at the 2023 World Conference on Lung Cancer (WCL23) demonstrated. The ability of the tumor-targeting agent, Vgt-309, to illuminate tumors could help surgeons more precisely locate tumors, better ensure clean margins and guide care decisions. In 10% of cases, the agent revealed unknown tumors in lymph nodes, which could affect which nodes are biopsied as well as when or whether a systemic therapy is recommended.
ITM SE has closed a €255 million (US$272 million) round to prepare for market entry, as its lead targeted radiopharmaceutical ITM-11 nears the end of phase III development in the treatment of neuroendocrine tumors of gastroenteric or pancreatic origin.
Imaginab Inc. has selected and advanced into IND-enabling studies IAB-56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3-targeting program, IAB-57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later this year.
Ariceum Therapeutics GmbH is picking up where Ipsen SA left off and taking forward the targeted radiopharmaceutical drug satoreotide, developed by the French pharma to phase II but subsequently divested when it ditched its radiation therapy portfolio.
HONG KONG – Hutchison China Meditech Ltd.'s (Chi-Med) is preparing for the next step after surufatinib achieved its primary endpoint in a phase III SANET-ep study in extra-pancreatic advanced neuroendocrine tumors (NETs) in China.
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) is preparing for the next step after surufatinib achieved its primary endpoint in a phase III SANET-ep study in extra-pancreatic advanced neuroendocrine tumors (NETs) in China.